Nick
Showing 31–32 of 32 transcripts.
- Milken Institute1h 1m
Is There Mojo in M&A?
Robert Rankin, Jonathan Coslet, DA, Ray, Steven, Nick, Rosie Greer
A resurgence in global M&A volumes, projected to reach $3.5 trillion this year, is driven by robust financing liquidity and a strategic shift by corporate boards from balance sheet repair to growth-focused acquisitions. While Private Equity participation remains normalized at 5% of total volume, heavy consolidation is occurring in pharmaceuticals, banking, and real estate sectors as firms navigate regulatory constraints and activist investor pressures. This market activity is further shaped by a bifurcated cost of capital that favors investment-grade borrowers and small private credit funds, forcing large deals to rely on alternative capital structures.
- Milken Institute58 min
The Role of Universities in Accelerating Bioscience Research
David Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
A consortium of leading academic figures, including Nobel Laureate David Baltimore and experts from Caltech, UCLA, and USC, convened to evaluate the intersection of biological engineering and clinical translation in the face of funding constraints. The panel detailed successful strategies for "engineered immunity" projects, such as converting muscle cells into antibody producers and conducting early-stage human trials within university settings, while highlighting the critical need for interdisciplinary programs that bridge the gap between engineering PhDs and MDs. Despite progress, participants identified a persistent "valley of death" in early-stage financing and urged a cultural shift toward professional management and team-based funding mechanisms to sustain innovation.